Virometix AG, of Schlieren, Switzerland, said it raised CHF1.2 million (US$1.3 million) from new shareholders in an extension to its recent series A financing round. The additional funds will be used to further accelerate development of its vaccine candidates for respiratory syncytial virus and cancer immunotherapy.